Immix Biopharma, Inc. 4

Director Helen C. Adams received 6,250 RSUs and a stock option for 12,500 shares of Immix Biopharma, Inc. common stock at $8.78 per share as equity compensation.

On May 22, 2026, director Helen C. Adams received an equity compensation package from Immix Biopharma, Inc. consisting of 6,250 restricted stock units (RSUs) of common stock and a stock option to purchase 12,500 shares at an exercise price of $8.78 per share under the company’s 2021 Equity Incentive Plan. The RSUs will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 annual stockholders’ meeting, contingent on her continued service. The stock option will vest in substantially equal monthly installments over 12 months following the grant date (or will fully vest at the 2027 annual meeting if that occurs earlier), also subject to continued board service. Following these grants, Adams held 181,004 shares of common stock directly and an option for 12,500 shares, representing an increase in her equity-based incentives but no open-market purchases or sales.

Filing Facts

CIK

1873835

Ticker

IMMX

Form

4

Source Type

sec

Accession

0001493152-26-026429

Alert Tier

5